Valeria Mollica Poeta

Valeria Mollica Poeta

Auto-generated profile, based on publicly available information

Valeria Mollica Poeta

Humanitas Clinical and Research Center, Rozzano, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
VPValeria Mollica Poeta
Valeria Mollica Poeta
MMMatteo Massara
Matteo Massara
ACArianna Capucetti
Arianna Capucetti
RBRaffaella Bonecchi
Raffaella Bonecchi
Immunotherapy is a clinically validated treatment for many cancers to boost the immune system against tumor growth and dissemination. Several strategies are used to harness immune cells: monoclonal antibodies against tumor antigens, immune checkpoint inhibitors, vaccination, adoptive cell therapies (e.g., CAR-T cells) and cytokine administration. In the last decades, it is emerging that the chemokine system represents a potential target for immunotherapy. Chemokines, a large family of cytokines with chemotactic activity, and their cognate receptors are expressed by both cancer and stromal cells. Their altered expression in malignancies dictates leukocyte recruitment and activation, angiogenesis, cancer cell proliferation, and metastasis in all the stages of the disease. Here, we review first attempts to inhibit the chemokine system in cancer as a monotherapy or in combination with canonical or immuno-mediated therapies. We also provide recent findings about the role in cancer of atypical chemokine receptors that could become future targets for immunotherapy.

26 October 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
MMMatteo Massara
Matteo Massara
PPPasquale Persico
Pasquale Persico
OBOrnella Bonavita
Ornella Bonavita
VPValeria Mollica Poeta
Valeria Mollica Poeta
MLMassimo Locati
Massimo Locati
RBRaffaella Bonecchi
Raffaella Bonecchi
Neutrophils are the most abundant white blood cells and are the first recruited to inflammatory sites. Neutrophils are an important component of the tumor stroma and can exert both antitumoral and protumoral activities, depending on their maturation and activation state. In human gliomas, the number of circulating and infiltrating neutrophils correlates with the severity of the disease, indicating a prognostic and possible pro-tumoral role for these leukocytes. In glioma preclinical models, neutrophils promote tumor growth and orchestrate the resistance to anti-angiogenic therapies. Nevertheless, recent data indicate that neutrophils can be activated to directly kill tumor cells or to orchestrate the antitumoral response. Here, we review current knowledge about the role of neutrophils in glioma and their possible involvement in new strategies to improve current cancer therapies.

14 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMatteo Massara
Matteo Massara
OBOrnella Bonavita
Ornella Bonavita
Benedetta SavinoBenedetta Savino
Benedetta Savino
NCNicoletta Caronni
Nicoletta Caronni
VPValeria Mollica Poeta
Valeria Mollica Poeta
RBRaffaella Bonecchi
Raffaella Bonecchi
Atypical chemokine receptors (ACKRs) are regulators of leukocyte traffic, inflammation, and immunity. ACKR2 is a scavenger for most inflammatory CC chemokines and is a negative regulator of inflammation. Here we report that ACKR2 is expressed in hematopoietic precursors and downregulated during myeloid differentiation. Genetic inactivation of ACKR2 results in increased levels of inflammatory chemokine receptors and release from the bone marrow of neutrophils with increased anti-metastatic activity. In a model of NeuT-driven primary mammary carcinogenesis ACKR2 deficiency is associated with increased primary tumor growth and protection against metastasis. ACKR2 deficiency results in neutrophil-mediated protection against metastasis in mice orthotopically transplanted with 4T1 mammary carcinoma and intravenously injected with B16F10 melanoma cell lines. Thus, ACKR2 is a key regulator (checkpoint) of mouse myeloid differentiation and function and its targeting unleashes the anti-metastatic activity of neutrophils in mice.

11 January 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
OBOrnella Bonavita
Ornella Bonavita
VPValeria Mollica Poeta
Valeria Mollica Poeta
ESElisa Setten
Elisa Setten
MMMatteo Massara
Matteo Massara
RBRaffaella Bonecchi
Raffaella Bonecchi
The lymphatic system plays an important role in the induction of the immune response by transporting antigens, inflammatory mediators, and leukocytes from peripheral tissues to draining lymph nodes (LNs). It is emerging that lymphatic endothelial cells (LECs) are playing an active role in this context via the expression of chemokines, inflammatory mediators promoting cell migration, and chemokine receptors. Particularly, LECs express atypical chemokine receptors (ACKRs), which are unable to promote conventional signaling and cell migration whilst they are involved in the regulation of chemokine availability. Here we provide a summary of the data on the role of ACKR2 expressed by lymphatics, indicating an essential role for this ACKRs in the regulation of the inflammation and the immune response in different pathological conditions, including infection, allergy, and cancer.

1 September 2018 in Cytokine
Verified
Journal Article
Closed access
OBOrnella Bonavita
Ornella Bonavita
VPValeria Mollica Poeta
Valeria Mollica Poeta
MMMatteo Massara
Matteo Massara
AMAlberto Mantovani
Alberto Mantovani
RBRaffaella Bonecchi
Raffaella Bonecchi

1 January 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
OBOrnella Bonavita
Ornella Bonavita
VPValeria Mollica Poeta
Valeria Mollica Poeta
ESElisa Setten
Elisa Setten
MMMatteo Massara
Matteo Massara
RBRaffaella Bonecchi
Raffaella Bonecchi
Corrigendum: ACKR2: An Atypical Chemokine Receptor Regulating Lymphatic Biology